Accelerating the translation of medical research - 27 June

Mortality Rankings
Local authority Population Premature deaths/ 100,000
1 Kensington and Chelsea 157,711 238
2 Rutland 38,046 241
3 Wokingham 160,409 248
…………………………………………………………………………………………
148 Liverpool 478,580 491
149 Manchester 530,292 527
150 Blackpool 139,578 549
Overall Premature Deaths

Why ?
A better local economy equals better health
Economy Health

Why is it needed?
Population health
Academia
Connectivity
Clinicians
Expertise
Early phase trial
Translational research

How does it attract business?
Lab and office accommodation for business with links to:
Category 3 labs Key Opinion Leaders
Insectaries Academics
Grid Computing Route to market
Trial unit & tissue bank Bigger business
AHSN & NHS Innovation Investors

Disease Resistance
• Too difficult box
• Ignored diseases
• High R & D costs
• Not met through traditional businesses
• Cancer, Diabetes, Infection, Mental health
Accelerator has a strong focus

House keeping
• No fire alarms planned
• No food and drink in the drum
• Introverts – ask questions at:
• www.sli.do
• Enter code: #Accelerator
Accelerator

Contact me on:
Dr Steve Powell
Accelerator
T: 07768 178 341
E: steven.powell@rlbuht.nhs.uk

Munir Pirmohamed
David Weatherall Chair of Medicine
Department of Molecular and Clinical Pharmacology
Institute of Translational Medicine
University of Liverpool
Precision Medicine

Current Paradigms
 As physicians, we all “personalise” treatments
 We use the best evidence available to us (usually
from RCTs – population based studies) to treat the
patient (i.e. individual) consulting us
 From a population perspective, that has proven
benefits
 But from an individual perspective, it is less
satisfactory
 Cannot predict whether the patient will
improve
 Cannot predict whether the patient will
develop side effects
Sir William Osler (1849-1919)
“Variability is the law of life”

Definition of Precision Medicine
 Precision medicine is an emerging approach for disease treatment and prevention
that takes into account individual variability in genes, environment, and lifestyle for
each person
2015
Obama’s Precision
Medicine Initiative
$215 million

Systems Approaches
Buy your own microbiome
Do-it-yourself faecal transplant –
courtesy of Youtube

Sensors
 Conventional engine control unit – dozens of data points/sec
 Flight data recorders – 3000 data points/sec (2GB per flight)
 Newborn baby – in 1952 APGAR test introduced – 5 data points – this is
what we use today!
"Before AliveCor it was really frustrating trying
to get doctors to take me seriously because I am
young and healthy, but I knew something wasn't
right. AliveCor FINALLY got their attention and
now I am being treated."
Change in doctor-patient relationship

Serious Adverse Drug Reactions
Toxic Epidermal Necrolysis
Hepatocellular hepatitis

HLA-B*57:01 and Abacavir Hypersensitivity
CHANGE IN INCIDENCE OF ABACAVIR HYPERSENSITIVITY
AFTER INTRODUCTION OF PROSPECTIVE GENOTPYING
 Cost effective

Associations of Serious Adverse
Drug Reactions with HLA Alleles

HLA Platform
Mr SPOT
Histomatch software
Standard type of wells with the SSO
spotted on to the base of the well in a set
pattern which can be recognised by the
Histomatch software

Analytic Validation
 Platform was able to call risk alleles with 100% accuracy at all the
loci (n=187 healthy volunteers)
85% have at
least 1 risk allele
Use
• At time needed
• Store data on EHR
• Pre-emptive genotype
Number of Risk Alleles per
sample
Number of Samples
% of
samples
0 28 15.0
1 39 20.9
2 14 7.5
3 46 24.6
4 34 18.2
5 11 5.9
6 6 3.2
7 8 4.3
8 1 0.5

GWAS Warfarin Mean Weekly Dose
(UK Prospective Cohort; n=714)
CYP2C9
VKORC1
Total = 57.9%
Age: 11.2%
Height 3.56%
Weight: 5.98%
Interacting meds: 0.98%
Sum of interacting meds: 2.2%
VKORC1: 25.61%
CYP2C9: 16.65%
CYP4F2: 0.49%

Warfarin RCT (NEJM, 2013)
• EU-PACT
• UK/Sweden
• 7% improvement in
time in therapeutic
range at 3 months

VK
*3
*2
ParaDNA: Point of Care Device
1. Take sample
2. Use device to transfer and
seal sample into four wells
pre-loaded with single or
multiplex test chemicals
3. Four separate
independent
analyses possible
4. Analysis is complete in
45 minutes.
30Courtesy of LGC, Commercial in Confidence
Sample Dispense
Three genotyping tests
(VKORC1, CYP2C9*2, *3)

Next Steps
 Interim analysis of implementation study – evaluate effect size and cost-
effectiveness
 Engage with commissioners
 Engaging with NHS England
 LGC introduced to American researchers with a view to developing POC
testing for African-American alleles
 New study about to start in Uganda and South Africa
 Potential for interacting in the Far East
 Introduction to world-wide markets because of our reputation in this area.

RECRUITMENT LOCATION ENGAGEMENT GENETICS
Aims to recruit 3000 healthy
volunteers, of which 1000
participants from this cohort
to be of Chinese origin.
Current participant
recruitment rates indicate
that the target should be
achieved by March 2018.
Recruitment has begun at two
sites across the country. Both
NHS & Non-NHS sites are being
utilised for recruitment. Royal
Liverpool Hospital & Convance
CRO (Leeds) in partnership to
achieve study objectives
Leeds
Liverpool
Development of a active
community for volunteers to
enhance recruitment into future
phase I studies irrespective of
their location. Social media tools
will harness the real time access
to information a study of this
type requires.
DNA will be genotyped for
polymorphisms in drug
metabolizing enzymes and
transporter genes. This genotype
profile has the potential to then
be utilised when developing
generic pharmacokinetic models
predicting doses according to
genotype

Personalised (Precision) Health
 University wide research theme
 A lot of interest all over the world- but quite a lot is aspirational
 In certain areas, in Liverpool, we have already delivered
 Plans going forward is to further engage with Industry
Pharma Diagnostics
Devices Informatics

• Regulation of Genomics (MHRA)
• Health Economics for Stratified Medicine
(Academy of Medical Sciences)
• Re-engineering of clinical pathways to
facilitate implementation of personalised
medicine (NHSE)
Addressing the challenges of
delivering stratified medicine

Innovate UK Case Study
- MAST Diagnostics
Presented by Jon Hobson
Date: 27/06/17

MAST GROUP Ltd.
• SME (c.130 employees)
• Manufacturer of in vitro
diagnostic products (IVDs)
• Established in 1957
• Located in Bootle,
Merseyside
• 4 Locations Servicing
over 70 countries

Celebrating 60 years as an independent manufacturer
and supplier of laboratory tests for the diagnosis of
infectious disease

Celebrating 60 years as an independent manufacturer
and supplier of laboratory tests for the diagnosis of
infectious disease
“After 60 years we must be doing something right”

McDonald T, Pearson N, Johnson F, O‘Grady FW. J Med Eng Tech. 1981; 5: 243-245
Introducing Automation
Involvement in automation began in 1983
with the launch of the Mastascan system
The system evolved into the current urine
screening system developed from a
University of Liverpool KTP programme

• Approximately 75% of urines specimens processed in
Greater London are interpreted using a
• From 1,500 entries throughout the UK

What can the MastUri™ System do?

An Opportunity
Loop-mediated isothermal amplification (LAMP)*:
• A novel isothermal gene amplification method
• Four specific primers recognise six distinct regions of the target DNA
• Characterised by self priming DNA synthesis and visible end point
• Driven by large fragment Bst DNA polymerase with enhanced strand
displacement activity
• Suited to Point of Care/Point of Need testing
* Licensed under International Patent application numbers:. WO 00/28082, WO 01/34790, WO 01/34838,
WO 01/83817, WO 01/77317, WO 02/24902, WO 02/103053
and corresponding patents owned by Eiken Co., Ltd., Japan in other countries.

Remit: A point of care assay for detection
of Neisseria gonorrhoeae and Chlamydia
trachomatis from a urine sample in a
clinic
Time to result: 1 hour
Rationale: To be able to prescribe
appropriate treatment before the patient
leaves
Looking for a Solution

South West Regional Laboratory
Our Partnership

Industrial and lead partner: commercial exploitation,
development of assay reagents and diagnostic platform
Sample preparation, culture of organisms,
determination of limits of detection
Optical readout, molecular diagnostic platform software
and electronics design
Clinical input and evaluation, molecular assay development
Expertise of Project Partners

• Managing the project
• Frequency of meetings
• Skype calls
• Quarterly reports and meetings
• Appointed monitoring officer
Structuring the Project

Comprised of clinicians and sexual health workers
• Extension of project scope
• Definition of sample type
• Provided essential feedback on development
The Focus Group

• PhDs awarded: one each at UoL and LJMU, (embargos on theses)
• Peer-reviewed articles and IP creation (Patents granted)
• Conference presentations
• Reagent methodologies and Diagnostic platform
• Assay exploitation (LJMU): Food authenticity testing
• MAST ISOPLEX® Lyo kits
Product & IP Outcomes

Urine
Sample
Nucleic Acid
Extraction
Amplification of
target using
LAMP*
Real time analysis of
optical output
All steps conducted in a single
point of care device
* Licensed under International Patent application numbers:. WO 00/28082, WO 01/34790, WO 01/34838, WO 01/83817,
WO 01/77317, WO 02/24902, WO 02/103053 and corresponding patents owned by Eiken Co., Ltd., Japan in other countries.
The Diagnostic Assay

Benchtop extraction
On-device extraction
Time (1 unit = 1/88th of one minute)
9 mins
23 mins
Target 1:100fg
TARGET 2 :100fg
Target 3: 10^1 copies
Target 4:1pg
Target 5: 100fg
Target 6:100fg
Target 7: 1pg
Extraction & Amplification Efficiency

QC –
Amplified
Product
Kit
Manufacture
Integration of new product manufacture and processes:
Operations Management

• New buildings
• New facilities
• New staff
Not Just a Product

Growing long term relationships
Developing innovative products
Building multidisciplinary teams
Providing mutually beneficial outcomes
Managing expectations
What We Learnt

Growing long term relationships
Providing mutually beneficial outcomes
Developing innovative products
Building multidisciplinary teams
Managing expectations
What We Learnt
Continuing “to do something right” to the next Anniversary

Sensor City
Sensors for Health
On Behalf of Sensor City Team
Professor Ahmed Al-Shamma’a

Sensor City
Fully Operational June 2017

What is Sensor City?
• A Liverpool-based technical innovation centre and University Enterprise Zone.
• Fostering the creation, development, production and promotion of cutting
edge sensor technologies for use in a range of sectors.
• Operating out of a 2,500m2 purpose-built technical and business support
centre, designed to meet the needs of our industry partners (opens June 2017).
• A collaboration between University of Liverpool and Liverpool John Moores
University.

A Flagship University Enterprise Zone
Sensor City Liverpool Limited
– £5m BEIS
– £5m ERDF (ESIF 2014-20)
– £2m industry match
– £1.5m from both Liverpool John Moores University and University of Liverpool

Vision
By working collaboratively, and creating a connected sensor
community, we aim to make Liverpool a global hub for sensor
technologies.

Sensor City objectives
– Provide purpose-built accommodation in a city centre innovation hub
– Increase SME innovation
– Integrate an established academic base with industry
– Establish and support a connected sensor community

Supporting regional/national innovation assets

Sensor City facilities
– State-of-the-art equipment and technical support
.
– Technology development zone
• Integrated open laboratory services
• Software development support
• Electronics lab
• Shared equipment
• ..
– Open innovation lab with ‘sandpit’ model to support problem solving,
innovation and collaborative design
.
– Shared meeting rooms, workshop and break out areas
.
– Located close to universities and access to further facilities

Sensor City support
– Academic expertise
– Entrepreneurship coaching
– Business mentoring
– Networking support & events
– Industry-partnered student
internships
– Access to funding & scholarships
– Active investor network

Sensors for Health
Case Studies

• Non-ionising
• Good penetration
• Relatively inexpensive
• Good versatility
– Designs to suit application
• We have developed many
different types of sensor to
suit different usage.
Electromagnetic Wave Sensing

Some theory…
Port1
Port2
Input
power
S11 (reflected power)
Microwave
Cavity
S21 (transmitted power)Port1
Port2
Sample
22
2













d
l
a
pc
f nm
rr
nml


A change in sample εr results
in shift of resonant frequency
Pozar, D. M. 1998. Microwave Engineering 2nd Edition, John Wiley & Sons, ISBN 0471170968.

Field interaction
TM010 TM210 TM220TM310
Increasing frequency

Non-invasive wireless sensors to track
physiologic signs and biochemical
markers
Left, experimental setup, showing participant on ergometer with sensors attached and appropriate data
acquisition hardware; right illustrates placement of sensors on both arm and leg with another participant.

Enuresis Detection
(a) is an image with
a dry sensor
(b) is a photo 1 sec later as the
Urine has been placed on the
sensor showing the prototype
communicating wirelessly to a
mobile phone through Bluetooth.
Graph showing the sensor output distinguishing
between sweat, water, urine and urea concentration.

Enuresis Prediction
Photos of prototype 2 working at 868MHz with a smaller footprint and also
movement and temperature sensors incorporated for prediction algorithm
Sensor
Movement
sensor board
Microcontroller
and temperature
sensor
Frequency generation
and detection board

Cannula Monitoring
• 85% of all hospital patients have a
cannula: 29% of these cause
infiltration and extravasation with
minor to major effects
• From Jan 2013 to Dec 2015, 64
severe cases recorded at Alder
Hey
• We propose a disposable wireless
sensor placed over the cannula
dressing to detect water
differentials that change due to
extravasation

Hackathon With the Health Care

The Future – Wireless Battery less

Technology Readiness Level
“Real” industry
involvement and
funding,
progress
accelerates. Likely trajectory
without industrial
engagement

Pharmaceutical industry
collaboration with the
NHS and universities
Professor Peter Timmins
Chair LCR Health & Life Sciences Board

Diverse models of collaboration
• Universities
• Commercial research (fee for service)
• Collaborative research, including
• Consortia
• Post-docs
• PhDs/KTPs
• Placements
• NHS
• Early phase units
• Clinical trials

Mechanistic Understanding of Adverse Drug
Reactions
University case study:
Centre for Drug Safety
Science
Slide from UoL

CDSS approach to improving drug safety
Chemistry of
the Drug
Biology of the
System
Variability of
the Patient
Improving
Drug Safety
Science
Safe Drug
Design
Innovative Use
of Bioanalysis
Organ-directed
Toxicity
Predictive
Models
Mechanistic
Biomarkers
Role of the
Immune System
Pharmacogenetics
of ADRs
HLA Restriction
Chemical Stress
Slide from UoL

Working with Industry
 Partner in several IMI-JU projects
 SAFE-T: clinical validation of organ-injury biomarkers
 MIP-DILI (Managing Entity): new model systems for predicting DILI
 Web-RADR: social media and big data in pharmacovigilance
 SafeSciMet: European safety Masters training
 TransQST (Co-ordinator): quantitative systems toxicology
 Several company-sponsored investigative projects for drug-specific ADRs
 CASE studentships
 All supported by a dedicated Industry Programme Manager
https://www.liverpool.ac.uk/drug-safety/
Slide from UoL

Case Study 2:
Centre for Collaborative Innovation in Dementia: Living
Lab Process
Health &
Social Care
Academia
BusinessCitizens
© The Centre for Collaborative Innovation in Dementia, 2017
Innovating

Funding Your Collaboration
LJMU Funding
(& UoL/LSTM too)
BBSRC LINK BBSRC Industry Partnership Award
MRC Industry Collaboration Award Innovate UK Knowledge Transfer Partnership
Slide from LJMU

NHS research – National Institute for Health Research (NIHR)
• NHS
• Early phase units
• NIHR Royal Liverpool & Alder Hey
• Clinical trials
• NIHR Clinical Research Network North West Coast

NHS research – National Institute for Health Research (NIHR)
• NIHR Clinical Research Network North West Coast
• Provides infrastructure that allows high-quality clinical
research to take place in the NHS
• Help to increase opportunities for patients to take part in
clinical research and ensure that studies are carried out
efficiently

www.liverpoolhealthpartners.org.uk
• Development of commercial research partnerships
• Maximise clinical trial recruitment opportunity for patients
• Deliver to time & target recruitment
• Gateway for PI’s/CI’s across Liverpool City region
Liverpool Health Partners - Industry Gateway Office
Slide from LHP

https://www.liverpool.ac.uk/research/collaborate/
https://www.ljmu.ac.uk/business/industry-and-business-engagement
http://www.lstmed.ac.uk/
http://www.alderhey.nhs.uk/research/nihr-alder-hey-clinical-research-
facility/
http://www.clinicalresearchliverpool.nhs.uk/
https://www.nihr.ac.uk/nihr-in-your-area/north-west-coast/
http://www.liverpoolhealthpartners.org.uk
Further Information:

FOLLOW US:
@innovationnwc
@LCRLifeScience
@investliverpool
@KQLiverpool
#translationalresearch Q&A details: www.sli.do
Enter code: #Accelerator
Accelerating the translation of medical research

Life Sciences Ecosystem in the North
Geoff Davison, Bionow
June 2017

a specialist business support and services company
Delivering tangible value to the biomedical sector in the North of England
Members include:
biotech, pharmaceutical, analytic, CRO, CMO, diagnostics, healthcare
and medical device companies plus the specialist supply chain
Our service spans procurement, insurance, recruitment, training, specialist
events and access into a vibrant network of businesses, Universities and the NHS
Bionow’s corporate and university sponsors share our vision for long term growth
Together we enable Bionow member organisations to be
the most productive and competitive in the world

Bionow Membership & Reach
• Bionow is the membership organisation for life science
businesses in the North
• 280+ subscribing members.
• Major corporates through to small SME members - AZ
corporate patron.
• Direct links with 1000+ businesses across the North
• Contacts at 3000+ life science businesses across the UK.
• Deliver events to 2000+ delegates annually.
• Significant national linkages – United Life Sciences – BIA,
One Nucleus, UKTI LSO, OLS, BIS, KTN, Innovate UK etc.
• Significant regional linkages - 8 Northern University
sponsors & 7 University Premium Members; NHSA; N8;
AHSNs; LEPs, key science parks & innovation centres etc.

Bionow Business Support
Bionow offers a suite of integrated business support services including:
• Mentoring
• Access to the NHS
• Lifescience Launchpad / Medtech Accelerator
• Knowledge Transfer Partnerships
• Student Placements and Projects
For more information visit
http://www.bionow.co.uk/support.aspx

Infrastructure for engagement
Bionow website www.bionow.co.uk
Members can Post News
Search/Post Jobs
Browse and Register for Events
Business B2B networking platform www.bionowb2b.co.uk
Members can create tailored ‘microsite’ to position a targeted sector message
Will shortly become a fully searchable version of the Bionow Directory
Social media
Bionow Ltd https://twitter.com/bionow
https://www.youtube.com/user/bionowchannel
Monthly Newsletter – available to all
Bi-monthly Member Review - 4Members

Some of our events in 2017/18
• Precision Medicine Conference – 5th April – Leeds
• Liverpool John Moores’ Showcase event, 16th May 2017
• Medtech Accelerator – 7 half days 12th April to 5th July, Daresbury
• BioFocus – 29th June 2017, Centre for Life, Newcastle
• R&I Event – Manchester Metropolitan University – 6th July
• Daresbury Business Pitching, 11th July
• School Career days – August
• BioCap 2017 and Investor Dinner – 27th & 28th September, Alderley Park
• BioInfect 2017 and pre-event Dinner 1st & 2nd November, Alderley Park
• BioEurope, 6th – 8th November, coordinating Northern Powerhouse presence with NHSA
• Bionow Annual Awards 2017 – 30th November, The Mere
• Genesis – exhibiting in London Dec 2017 as part of Northern presence
• Oncology event, Alderley Park, 28th February
• National specialist supply chain event with One Nucleus 2018
• All events at www.bionow.co.uk/events

The North
• Northwest, Northeast and
Yorkshire
• Includes the city regions of
Liverpool, Manchester, Lancaster,
Sheffield, Leeds, York, Durham &
Newcastle
• Described in the Bionow
Northern Life Science and
Healthcare Directory
• 1000 life science and healthcare
businesses

North of England life science companies
Strength & Opportunity 2013 (without pharma)
628
694
626
358
503
348
258
336
246
135
271
61
841
0 100 200 300 400 500 600 700 800 900
East of England
South East
West Midlands
Yorkshire and the Humber
East Midlands
North West
Wales
Scotland
South West
North East
London
Northern Ireland
The North
Company numbers across UK regions
The North
• 1000+ life science and healthcare
businesses
• Combined turnover £10.9bn
• Employment of 38,000
• Exports of £7.3 billion medicinal and
pharmaceutical products in 2015 equating
to 44.7 per cent of UK exports

Biotech and
Pharmaceutical
21%
CRO
10%
CMO
6%
Diagnostics
8%
Analytical
9%
Medical Technology
26%
Healthcare
15%
Industrial / Agri Biotech
5%
Northern company base
Around 25% of the total number of life science businesses in the UK – good
representation across the value chain
Category Numbers of Companies in the
North
Biotech and Pharmaceutical 98
CRO 47
CMO 30
Diagnostics 39
Analytical 42
Medical Technology 119
Healthcare 72
Industrial / Agri Biotech 21
Core Company Total 468
Specialist supply chain 531
Total 999
Manufacturing strengths in all these
subsectors – with particular hubs in NW (Speke
& Macclesfield) and the Northeast

Particular industrial strengths of the North
• (Pharma, chemical, vaccine, bio) Manufacturing
• Biotech & Pharma
• Specialist supply chain (CRO, CMO, Analytics etc.)
• Infection (incl. AMR)
• Precision Medicine (incl. diagnostics)
• Management & delivery of clinical trials
• Wound care & orthopaedics
• Med Tech
• Digital Health

Northwest company base
Biotech
15% Pharmaceutical
8%
CRO
12%
CMO
5%
Diagnostics
8%
Analytical
7%
Medical Technology
22%
Healthcare
21%
Industrial / Agri Biotech
2%
A leading (top 3) UK region with a full offering across the value chain – from
discovery to market

Particular industrial strengths in Liverpool
An important cornerstone in the Northern Powerhouse with key strengths in:
• (Pharma, chemical, vaccine, bio) Manufacturing – a key centre
• Major strengths in translational infection research – CEIDR, LSTM
• Precision Medicine (incl. diagnostics)
• Management & delivery of clinical trials
• Med Tech
• Digital Health
Lots of synergies with the North and lots of examples of companies working
globally and growing their businesses..

A few examples of growing, connected businesses in
Liverpool
Liverpool ChiroChem - supply chiral compounds to pharmaceutical research companies across North of England and
beyond.
Videregen - Part of Horizon 2020 research project in regenerative medicine
Evgen plc – AIM listing and have multi-centre Phase II clinical trial in patients with ER+ metastatic breast cancer
Mast Group – Innovate UK grants, extensive range of microbiology and immunology products and global network
Pro Lab Diagnostics - European HQ, distribute and manufactures products within the immunodiagnostics area. A
strategic alliance with the Animal & Plant Health Agency and part of the worldwide Pro-Lab Group.
Plus Major Corporates:

Collaborative working Bionow & NHSA

A functioning health partnership for the North of England
To maximize the impact of health science
research and to provide a go-to center for
healthcare companies we have created the
Northern Health Science Alliance (NHSA), a
collaboration between eight of England's great
cities across a population of 15m people.

Precision Medicine Population / Digital HealthHealthy Ageing
Research Themes
eHEALTH & DATA ANALYTICSCLINICAL TRIALS & Health Economics
• Two Precision Medicine Catapults
• Four Genomic England Centres
• Two NIHR Diagnostic Evidence Cooperatives (Leeds /
Newcastle)
• Two MRC / EPSRC Pathology Nodes
• New Medicines Technology Catapult
• Two MRC Single Cell Genomic Centres
• The UK AMR Centre at Alderley Park
• Cancer Research UK Manchester Institute
• Cancer Research UK Leeds Centre
• Cancer Research UK Newcastle Centre
• Astbury Centre (Leeds)
• National Centre for Ageing Science & Innovation in Newcastle
• MRC Arthritis UK Centre for Integrative Musculoskeletal
Ageing
• NIHR Newcastle Biomedical Research Centre in Ageing &
Chronic Disease
• Alder Hey Children’s Hospital
• York Neuroimaging Centre (YNiC)
• Centre for Hyperpolarisation in Magnetic Resonance (CHyM)
• SITraN in Sheffield
• Centre for Ageing Research (Lancaster)
• NIHR funded centres for Public Health research
• ESRC Centre for Translational Research in Public
Health
• Institute of Infection & Global Health, University of
Liverpool
• Well North
• Three NHS England Test Beds
• Liverpool John Moores University's Research
Institute for Sport and Exercise Sciences (RISES)
• CATCH in Sheffield
• NIHR Clinical Research Networks
• Several Clinical Research Facilities, three in Manchester alone
• MRC Network of Hubs for Trials Methodology Research
• Sheffield School for Health Related Research
• York Health Economics
• NWeHealth FARSITE trials recruitment tool
• MRC eHerc, Farr Institute, NorthWest eHealth at Manchester
• MRC Medical Bioinformatics Centre in Leeds
• EPSRC Postgraduate Centre for Cloud Computing in Newcastle
• Sci-Tech Daresbury and The Hartree Centre
• eHealth SME cluster (Liverpool City Region)
• Connected Health Cities
• CHICAS, School of Health and Medicine.
Key Health Research Themes in the North
Digital Health approaches and technologies are deployed across
all research themes.

The North of England has a thriving life science sector
• Health and life science sector
accounts for £17.5 billion of
the North’s £305 billion
output (GVA)
• It is forecast to grow by
44.6% by 2030.
• The sector employs over
570,000 people with over
38,000 of those in highly
skilled private sector
positions across 1,000 life
science companies.

The Northern Triple Helix via N8, NHSA & Bionow
Academic, clinical and industrial engagement across the North:
• Under the “Life Science in the Northern Powerhouse” brand at national and international events e.g.
Genesis, BioTrinity, BIO International, Bio Europe etc.
• Regional activities such as joint conferences (e.g. Precision Medicine & Cancer)
• Coordinated responses to Government e.g. on Northern Powerhouse initiatives.
• Aimed at increased academic, clinical and industry engagement to drive economic growth and patient
benefit.

In summary…
• The North is a cluster of international scale with the Northwest representing
the cornerstone to this.
• There are opportunities & strengths across the whole value chain.
• Liverpool is a key component of the Northern cluster.
• International businesses locating here have found it a low risk place to do
business.
• The business support infrastructure is second to none, focused upon delivery
and high quality space is readily available.
• The support ecosystem is well connected, co-ordinated and collaborative and
aimed at de-risking business investment.
• .…plus it’s a great place to live and work!

Geoff Davison
07968 323381
geoff.davison@bionow.co.uk
www.bionow.co.uk
Thank you. Any questions?

AIMES Digital Health &
Research Infrastructure
Dr. Ed Conley
Chief Scientific Officer, AIMES,
Liverpool Innovation Park
Connected Health Cities Programme
ed.conley@aimes.net
Accelerating the
Translation of
Medical Research
27th June 2017

AIMES’ Core Interests
- Digital services for
learning health
systems and cross-site
federated
research
- Regional-scale
Health
Information Exchange
- Secure connectivity
and EPR system hosting

Pharma
133
Patients/
Citizens
Payers
Universities
Government &
Public Health
Local
Healthcare
Delivery
Systems
(Patient journey)
Research
Institutes
Biomedical
Data
Tech Industry
Learning Health
System Stakeholders
ALL PRODUCE AND
CONSUME DATA
Learning Health Systems Interfacing Challenge
participant consumers/producers of data and the research community
GPs, Consultants, Research Nurses
NHS Information Services, NHS Managers
Social Care, Ambulance, Emergency Services…
Strategic Planning
/Policy
3rd Sector organisations
Clinical Guideline
Committee Chairs
Local Authority
Innovation Agency
ABPI EHR & Medical
Device Vendors
Commissioning
Groups (CCGs)
Scientists
Technologists
Researchers
Statisticians
RECORD
HOSTING
& TRE

SCN
Collaborative Problem-Solving
North-West Coast Learning Health System

Authenticated Researcher(s)
Known
Machine(s)
Location(s)
Firewall
VPN/Portal
login
Virtual
Machine (VM)
Bespoke Apps
Compute-
Intensive
Services
Secure Research Data Host
Connected Health Cities
Trustworthy Research Environment
Researcher view
TRE

The foundations…
ISO27001
(baseline)
Physical
Perimeter
Security
Resiliency
+ Fail-safe
Multiple
Utility/UPS
Power
Secure
Networking
Health and Social
Care Network
HSCN
For NHS Record Hosting & Distributed Clinical Research Partnerships…

Cerno Health is the master distributor for United Imaging in the UK & Republic of Ireland
Dr. Min Xue, Chairman of the Board & Chief Executive Officer, UIH
and Mr Gary Disley, Managing Director, Cerno Health following
the signing of the Master Distributor agreement in Shanghai, China.

Exclusive Distributor of UIH equipment in the UK & the Republic of Ireland
CERNO HEALTH LTD
Media House : Boyton Hall : Roxwell Road: Chelmsford : Essex : CM1 4LN : United
Kingdom
T: +44 333 301 0312 F: +44 333 301 0311
E: info@cernohealth.com W: www.cernohealth.com

Acceleration For Global
impact
Janet Hemingway
Director Liverpool School of Tropical Medicine

Vector Biology an Example
• Malaria
• Dengue
• Leishmaniasis
• Trypanosomiasis
• Zika
• Chikungunya

Text
Novel Interventions and Enabling Technologies
for Insect Borne Disease Prevention
Challenges and approaches
to encourage
the development
of innovative
vector control tools

NIHR Health Protection Research Unit in Emerging and Zoonotic Infections
IVCC is a Product Development
Partnership investing donor funds in
R&D to overcome barriers to
innovation in vector control
IVCC supports the malaria elimination
and eradication agenda with a focus
on bringing new tools and products to
failed markets that can combat the
rapidly growing problem of insecticide
resistance
A new Vector Control Product Development Partnership (PDP)

Bridging Public Health Needs and Innovation Barriers
Translational Focus
Development Focus

Product Development Partnerships
• New Insecticides
• New formulations
• Improved Diagnostics
• IT systems

Developing Products Through Partnerships

Projects require partnership with Industry and Academia, overseen by Expert
Scientific Advisory Committees (ESACs)
ESAC
oard of Trustees
ESAC1
0
2
4
6
8
10
Efficacy
Implementati…
Safety
Regulatory
IP
End User…
Ability to…
Resistance…
Spectrum
Speed of…
Environment…
Cost of Goods
Toxicology
Mode of action

Impact of Northern Ghana
• Actellic CS developed by
Syngenta is the first long lasting
non-pyrethroid IRS formulation
( 3rd Generation IRS)
• We supported trials to
demonstrate safety and efficacy
allowing early adoption by PMI
• Initial data from PMI
implementation shows
outstanding impact
Bunkpurugu-Yunyoo district, Northern Ghana
Control program data from Abt and PMI, In preparation for publication

153
LSTMs Translational Pathway supporting staff
development and Impact

Consumer Products
• Does my product ‘work’?

Developing and applying DNA markers to predict
insecticide resistance
0
5
10
15
20
25
30
35
40
0 500 1000 1500
Moshi alive (resistant) vs Tarime (susceptible)
• Risk of insecticide failure is a major challenge for disease control and can be aided by widespread,
high volume data from molecular diagnostics to feed into disease management systems
• We apply transcriptomic and genomic approaches to discover markers for insecticide resistance in
wild caught vectors
• Markers are tested for predictive value and geographical relevance

Public Health Products
• Indoor Residual Treatments
• Long lasting nets
• Tiny Targets
• Larvicides

Examples of application and challenges
Increase in Ace-1 marker in Anopheles gambiae predicts extreme resistance
to carbamate insecticides in southern Ghana
Possession of kdr resistance markers by sandflies P. argentipes
predicts human blood feeding in Bangladesh
Human Non-human
Wild
type
(blue)
Marker development also
underway for Aedes.
Challenge: how to apply
information in urban, rather
than rural settings more
typical for malaria and
leishmaniasis

• Improving diagnostics
• Defining the spectrum of
neurological disease
• Mosquito control
• Understanding the
immune response to
develop treatments and
vaccines
Liverpool Response to
Zika Outbreak in Latin America

saving lives
vectorcontrol
Questions?

Presentation 1
Dr Liz Mear
Chief Executive

What are AHSNs?
We are licenced by NHS England to:
• Speed up adoption of innovation into practice to improve clinical outcomes
and patient experience
• Support economic development through co-development, testing,
evaluation and early adoption and spread of new products and services
Focusing on the needs of patients and local populations and building a culture
of partnership and collaboration

National Reach and Local Delivery
• Nationally we collaborate as a strong network of 15 - operating across health and
care to deliver improvement at pace and scale. Collectively we support an number
of national programmes including
• NHS Innovation Accelerator
• Health SBRI
• Innovation Pathway
• Patient Safety Collaboratives
• Locally we act as honest brokers within our regions, mobilising expertise across the
NHS, academia and industry to help improve lives, save money and drive economic
growth.

Who do we work with?
Nationally
• NHS England, NHS Improvement and the Department of Health / Public Health England and Office for Life Sciences
• Representative bodies such as the ABHI and ABPI (representing industry), NHS Clinical Commissioners and NHS Providers
• NICE
• Third sector organisations such as charities and patient representative groups
Locally
• NHS provider trusts
• Clinical Commissioning Groups and other commissioning organisations
• Public health and social care organisations including local authorities
• Local transformation partnerships such as Sustainability and Transformation Partnerships (STPs)
• Local Universities and NIHR organisations such as CLAHRCs, Clinical Research Networks and Biomedical Research Units / Centres
• Local NHS organisations such as Strategic Clinical Networks and Senates
• Local Economic Partnerships
• Industry and cluster groups such as MediLinks, Bionow

Idea Proof of concept Adoption Spread
Innovation and Technology Payment (NHSE)
Central reimbursement of innovative products, services
and technologies
NHS Innovation Accelerator (NHSE)
Supporting a small number of fellows to spread
their innovations in the NHS
Accelerated Access Partnership (OLS)
Comprised of cross health economy stakeholders, supporting the development of transformative
products, services and technologies via existing routes
NHS Apps Library (NHSD)
Setting standards for apps looking to be
used in the NHS
Health Apps Briefing (NICE)
Assessment of the economic and
efficacy of apps
Test Beds (NHSE)
Pioneering and evaluating the use of novel combinations of
interconnected devices
Small Business Research Initiative (NHSE)
Provides funding to develop innovative ideas to NHS problems
Invention for Innovation (NIHR)
Provides funding for development of
prototypes
There are a number of initiatives supporting the identification and adoption of
innovative products, services and technologies
OLS
NHSE
NIHR
NICE
NHSD

National Innovation Accelerator
Apply: http://nhsaccelerator.com/
Applications will be accepted from 14 June 2017 to midnight on 26 July 2017.
Interview dates: 26 – 28 September 2017.
Confirmation: Successful applicants will be contacted on 12 October 2017.

The Innovation and Technology
Payment (ITP)
• The ITP aims to support the NHS in adopting innovation by removing financial or procurement barriers to uptake
of innovative products or technologies.
• Competitive process to identify innovations and technologies that will offer the greatest quality and efficiency
benefits with wider adoption.
• The ITP is looking to support medical devices, digital platforms and technologies. The programme is not suitable
for pharmaceutical products or research projects.
• select a range of cost effective innovations within budgetary confines
• a wide-reaching impact on patient care
• maximise learning and foster culture change.
• ITP is specifically focused on low cost innovations which can deliver significant patient outcomes and savings to
the NHS.
• The programme will be delivered in partnership with the AHSNs, sponsors, national and international experts.
• Applicants can be from healthcare, academia, commercial or voluntary sectors.
• Agreed payment mechanism or procurement will be operational from April 2018.
• Day-to-day support and reporting via NHS E’s Innovation and Research Unit.

SBRI Health
SBRI Healthcare is an NHS England funded initiative led by the Academic Health Science Networks to develop
technology solutions for known healthcare challenges. Our focus for Summer 2017 is Cancer, screening and
accelerated diagnosis as well as solutions for improved management of those who have survived.
• Applications for innovations that can enhance the screening, diagnosis or management of cancer.
• Up to £100,000 of funding for Phase one (feasibility) and up to £1m for Phase Two (development)
• A truly innovative offer that could transform screening, diagnosis or management of cancer.
• NHS needs will be provided in an SBRI Healthcare briefing document available the week commencing 24th July,
with briefing events London on Tuesday 25th and Manchester on Thursday the 27th.
The deadline for entries will be 4th September. Register at www.sbrihealthcare.com to receive the full briefing
and details (available from 25th July).

STOPandGO
Sustainable Technology for Older People – Get
Organised
• Public Procurement of Innovative Solutions (PPI)
01/04/14 – 31/01/18
• Benefit to 5000 people across Europe
• 15 Partners in Spain, Italy, the Netherlands and the UK
• FP7 contributes €3.446m to existing commitment
€17.23m
• Liverpool City Council due to receive minimum €600,000
(may rise to €1.2m)
• 4000 Domiciliary Care beneficiaries receive electronic
care plan

RITMACORE
Arrhythmias Monitoring and Comprehensive
Care
• Public Procurement of Innovative Solutions (PPI)
01/11/16–31/12/20
• 9 partners in the UK, Spain, Italy and the Netherlands
• H2020 contributes €4m to €7.5m of existing
commitment
• Liverpool Heart and Chest to receive c €1m towards
remote monitoring
• Warrington Hospital as a potential participant €500k+

ENSAFE
Elderly-oriented, Network-based Services
Aimed at Independent Life
• Funded under H2020 Ambient & Assisted Living
Programme
• SE, IT, NL and UK partners piloting integrated
technology solution
• Aims to introduce new products to market 2 years
after project end
• Focus on the technology vs commercialisation
opportunities

• Largest healthcare initiative in the world-H2020
• 130 Partners (IBM, Roche, Sanofi, universities, research institutes)
• Aims to:
o Promote entrepreneurship
o Innovate in healthy living and active ageing
o Improving quality of life in healthcare across Europe

Three EIT Health Programmes:
Innovation; Campus; Accelerator
• Campus 2017- Digital Hospital Transformation Short Course 29/08/17-01/09/17
Budapest
o Digital healthcare trends and technologies and design of transformation
project
• Accelerator 2017 – Product Market Fit
o 15 awards of €25,000 for start-ups (restrictive criteria)
• Accelerator 2017– Proof of Concept/Headstart
o Local SME (Damibu) in receipt of €50,000 award

Applications submitted
• Innovation by Ideas – xFall (Falls prevention technologies and innovative
approaches)
o Research Institutes Sweden (RI.SE), University Polytechnic Madrid, Skane
Municipality and the Royal Pharmaceutical Society €2m (€248k 2018, €215k
2019)
• Innovation by Design - Make Health Fluidics Contest
• Commission for Atomic Energy (Fr), Medical Valley (De) etc €480k (€27k 2018)
• Accelerator – P/M Fit (improved criteria – SMEs not start-ups)
• Accelerator – Headstart/PoC 15 applications from SMEs

NIHR – i4i Mental Health Challenge
• To develop innovative technological solutions
that can influence the patient care pathway
and improve patient outcomes for mental
health conditions
• Winner takes all approach
• £5m application with Mersey Care - Suicide
and self harm reduction for people in their
care

Horizon 2020
The EU Framework Programme for Research
and Innovation
• Supported the submission of a proposal from
LJMU to H2020 (plus Aimes and Glow Media)
• ICAN – Personalised coaching for well-being
and care of people as they age
• 3 year proposal - €100k for IA

Next steps?
• Horizon scanning for funding opportunities
• Partners – ECH Alliance / EIP AHA / others?
• Priorities
• Knowledge assets
• Leaders in their field
• Specialist facilities
• Project (application) Champions

Next Steps for AHSNs proposed future
model 2018-2023
Role of the
AHSN
1
NHS
EnglandGovernment
NHS Improvement
Partner
Contributions, EU
funding, industry
funding, grants etc
Deliver AAR objectives – support
local assessment of technologies
and knowledge exchange;
promote spread of innovation
nationally.
Translate research into practice and build
stronger relationships with the
scientific/academic communities and
industry to develop solutions to
healthcare problems. Deliver Five Year
Forward View, Genomics advances, Test
Beds, Innovation and Technology
Payment, Digital Health, Diagnostics,
Medicines Optimisation.
Partnerships with academic and
research institutions, NHS
providers, commissioners, industry.
Coordination of the 15 Patient Safety
Collaboratives to improve the safety of patients.
Delivery of Developing People, Improving Care
Role of
AHSN
Network

In Summary
• AHSNs are catalysts for the spread of innovation at pace and scale - improving health,
generating economic growth and helping facilitate change across whole health and social care
economies
• AHSNs connect - as member organisations we are well placed to mobilise cross-sector
buy-in, developing powerful regional networks of NHS and academic organisations, local
authorities, third sector and industry: responding to diverse patient and population needs
through partnership & collaboration
• AHSNs create the right environment for relevant industries to work with the health and
social care system

THE IMPORTANCE OF INTERNATIONAL BUSINESS & INVESTMENT
Ellen Cutler Director of Investment Invest Liverpool
Health & Life Sciences lead contact:
Matt Biagetti
mbiagetti@investliverpool.com @mattbiagetti LinkedIn.com/in/mattbiagetti

Accelerating the translation of medical research - 27 June

Recomendados

Recomendados

Más contenido relacionado

La actualidad más candente

La actualidad más candente (20)

Similar a Accelerating the translation of medical research - 27 June

Similar a Accelerating the translation of medical research - 27 June (20)

Más de Innovation Agency

Más de Innovation Agency (20)

Último

Último (20)

Accelerating the translation of medical research - 27 June